SequelSEC

uniQure N.V. QURE

Pharmaceutical Preparations · CIK 0001590560 · Fiscal year ends 1231

Revenue
$18.09M
Fiscal year ended 2026-03-31
Operating income
-$191.74M
Fiscal year ended 2026-03-31
Free cash flow
-$172.56M
Fiscal year ended 2026-03-31

Valuation, from the filing

Public float$764.80MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$12.23Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue47.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin89.5%84th
Current ratio10.43x80th
FCF margin-1108.2%23th
Revenue YoY growth-40.6%27th
R&D / revenue873.9%72th
Net margin-1236.0%29th
SBC / revenue109.8%69th
Operating margin-1151.4%31th
Long-term debt / equity0.25x38th
CapEx / revenue2.7%58th

uniQure N.V. (QURE) reported revenue of $18.09M and net income of -$208.87M for the fiscal year ended 2026-03-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from uniQure N.V.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

uniQure N.V. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Revenue$18.09M
Cost of revenue$1.71M
Gross profit$16.38M
Operating income-$191.74M
Net income-$208.87M
Research & development$133.71M
Weighted-average diluted sharesUnavailable
Pretax income-$203.25M
Income tax expense$5.62M
Diluted EPSUnavailable
Selling, general & administrative$74.62M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

uniQure N.V. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Cash & equivalents$139.99M
Total assets$778.71M
Current assets$615.74M
Total liabilities$629.36M
Current liabilities$59.20M
Total equity incl. NCI$149.34M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$3.56M
Goodwill$24.81M
Long-term debt$49.94M
Accounts payable$4.40M

Cash flow

uniQure N.V. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Operating cash flow-$172.11M
Capital expenditures$453.00K
Investing cash flow-$243.16M
Financing cash flow$335.28M
Net change in cash-$77.12M
Stock-based compensation$18.36M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$13.19M

Derived

uniQure N.V. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Free cash flow-$172.56M
Gross margin90.6%
Operating margin-1059.7%
FCF margin-953.7%
SBC / revenue101.5%
Current ratio10.40x
Revenue YoY growth-10.4%
Net margin-1154.4%
R&D / revenue739.0%
CapEx / revenue2.5%
Long-term debt / equity0.33x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open QURE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-05-09View SEC filing
10-K · Filed 2025-02-27View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.